FIP Development Goal 12 [w]

Globally, we will have:

A national strategy and corresponding actions to collate and share workforce data and workforce planning activities (skill mixes, advanced and specialist practice, capacity). Without workforce intelligence data there can be no strategic workforce development.

Mechanisms

• An operational global pharmaceutical observatory

• Develop monitoring systems to identify workforce trends to enable decision making on deployment and supply of pharmaceutical workforce, noting that time-lags are often present in these activities.

• Ideally, this should be linked with stewardship and leadership for professional leadership bodies.

FIP Development Goal 12 [p]

Globally, we will have:

A comprehensive national strategy to collate, share and utilise intelligence on service provision, development, delivery and needs to inform evidence-based pharmaceutical services development, policymaking and funding decisions.

Mechanisms

• Develop agreed frameworks for the provision of professional services that include clear definitions, requirements and standards against which it becomes possible to assess service delivery and generate professional service intelligence.

• Develop and implement systems for collating data and gathering and processing evidence on service delivery and availability across all jurisdictions and populations at country level.

• Define and recognise at country level a set of minimum indicators and metrics for service intelligence.

• Develop integrated databases for service delivery, workforce and science intelligence. Develop mechanisms for the rigorous and transparent exchange and sharing of service intelligence with stakeholders, partners and other professionals at local, national and international level.

• Develop the capacity to utilise big data generated in practice and in science, and to perform horizon scanning, trends assessment and predictions (e.g. demographic evolution, health needs trends, pandemics and other emergencies).

FIP Development Goal 12 [s]

Globally, we will have:

Data-driven decision strategies to accelerate pharmaceutical research, development, manufacturing, and market approval of medical products in order to maximise clinical benefits for individual patients.

Mechanisms

• Enable access to virtual hubs for information sharing and enhancement of collaborations.

• Promote “open science” gathering of data and information to accelerate all aspects of pharmaceutical sciences as a means of enabling pharmaceutical research intelligence production.